Newsfeeds - Spark Newswire

2 minute read

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year

Today, 10:23 PM

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.

ADAG

1 minute read

Taysha Gene Therapies Announces Initiation Of Clinical Development Of TSHA-118 For The Treatment Of CLN1 Disease

By Benzinga Newsdesk

Today, 10:23 PM

CTA approved by Health Canada in November 2021; IND approved and open in 2019 Queen’s University selected as initial clinical site under the direction of Dr. Jagdeep Wahlia, principal investigator PPT1 enzyme

TSHA

20 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 16, 2021

By Benzinga Insights

Today, 10:23 PM

ABNB

1 minute read

Guggenheim Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $28

By Benzinga Newsdesk

Today, 10:23 PM

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $28.

TSHA

4 minute read

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré

By Shanthi Rexaline

Today, 10:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACAD

1 minute read

Taysha Gene’s Epilepsy Candidate Shows Encouraging Action In Preclinical Studies

By Vandana Singh

Today, 10:23 PM

Taysha Gene Therapies Inc (NASDAQ:TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy. Data…

TSHA

1 minute read

Taysha Gene Therapies Announces Late-Breaking Abstract And Poster Presentation On Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential For The Treatment Of Epilepsy Caused By SLCA13A5 Deficiency

By Benzinga Newsdesk

Today, 10:23 PM

Data presented at the American Epilepsy Society Annual Meeting TSHA-105 normalized electroencephalogram (EEG) and citrate levels and improved survival in both early treated juvenile and later treated adult

TSHA

18 minute read

Earnings Scheduled For November 10, 2021

By Benzinga Insights

Today, 10:23 PM

Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.

AACG

4 minute read

Taysha Announces Exclusive Option From UTSW To License Worldwide Rights To Clinical-Stage AAV9 Gene Therapy Program For CLN7 Disease, a Research Collaboration With UTSW To Develop Next-Generation Construct For CLN7 And A Grant Award To Batten Hope;

By Bill Haddad

Today, 10:23 PM

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central

TSHA

1 minute read

Taysha’s Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag

By Vandana Singh

Today, 10:23 PM

The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc’s (NASDAQ:TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-related epilepsy. Related: Taysha…

TSHA